Repligen Stock Performance
| RGEN Stock | USD 167.31 1.09 0.65% |
On a scale of 0 to 100, Repligen holds a performance score of 7. The company holds a Beta of 1.39, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Repligen will likely underperform. Please check Repligen's value at risk, as well as the relationship between the skewness and day median price , to make a quick decision on whether Repligen's historical price patterns will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Repligen are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of very weak technical and fundamental indicators, Repligen displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.95 | Five Day Return 0.92 | Year To Date Return 2.46 | Ten Year Return 631.54 | All Time Return 1.4 K |
1 | Repligen reports Q3 adjusted EPS 46c, consensus 42c RGEN | 10/28/2025 |
2 | Acquisition by Ralf Kuriyel of 4826 shares of Repligen subject to Rule 16b-3 | 10/30/2025 |
3 | Is Repligens Upbeat 2025 Outlook a Sign of Sustainable Competitive Strength | 11/03/2025 |
4 | Disposition of 2191 shares by James Bylund of Repligen at 151.21 subject to Rule 16b-3 | 11/18/2025 |
5 | Repligen Chief Operating Officer Sold 331K In Company Stock | 11/20/2025 |
6 | Disposition of 2000 shares by Anthony Hunt of Repligen subject to Rule 16b-3 | 12/04/2025 |
7 | Brown Capital Management LLC Has 125.04 Million Position in Repligen Corporation RGEN | 12/05/2025 |
8 | Whats Driving the Market Sentiment Around Repligen Corp | 12/10/2025 |
9 | Acquisition by Muir Glenn P of 3366 shares of Repligen at 26.12 subject to Rule 16b-3 | 12/16/2025 |
10 | Disposition of 275 shares by Dawes Karen A of Repligen at 161.0 subject to Rule 16b-3 | 12/17/2025 |
11 | Repligen Corporation to Present at J.P. Morgan 2026 Healthcare Conference | 12/18/2025 |
12 | Riverbridge Partners LLC Sells 24,644 Shares of Repligen Corporation RGEN | 12/22/2025 |
13 | Insider Trading | 12/31/2025 |
14 | Repligen Valuation Check As New Board Chair Signals Leadership Continuity | 01/07/2026 |
| Begin Period Cash Flow | 751.3 M | |
| Total Cashflows From Investing Activities | -86.4 M |
Repligen Relative Risk vs. Return Landscape
If you would invest 14,952 in Repligen on October 15, 2025 and sell it today you would earn a total of 1,779 from holding Repligen or generate 11.9% return on investment over 90 days. Repligen is currently generating 0.2062% in daily expected returns and assumes 2.2453% risk (volatility on return distribution) over the 90 days horizon. In different words, 20% of stocks are less volatile than Repligen, and 96% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Repligen Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Repligen's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Repligen, and traders can use it to determine the average amount a Repligen's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0919
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | RGEN | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Repligen is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Repligen by adding it to a well-diversified portfolio.
Repligen Fundamentals Growth
Repligen Stock prices reflect investors' perceptions of the future prospects and financial health of Repligen, and Repligen fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Repligen Stock performance.
| Return On Equity | 9.0E-4 | ||||
| Return On Asset | 0.013 | ||||
| Profit Margin | 0 % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 9.33 B | ||||
| Shares Outstanding | 56.29 M | ||||
| Price To Earning | 154.58 X | ||||
| Price To Book | 4.51 X | ||||
| Price To Sales | 13.39 X | ||||
| Revenue | 634.44 M | ||||
| Gross Profit | 365.19 M | ||||
| EBITDA | 80.26 M | ||||
| Net Income | (25.51 M) | ||||
| Cash And Equivalents | 596.51 M | ||||
| Cash Per Share | 10.75 X | ||||
| Total Debt | 686.25 M | ||||
| Debt To Equity | 0.23 % | ||||
| Current Ratio | 2.30 X | ||||
| Book Value Per Share | 37.01 X | ||||
| Cash Flow From Operations | 175.39 M | ||||
| Earnings Per Share | 0.02 X | ||||
| Market Capitalization | 9.48 B | ||||
| Total Asset | 2.83 B | ||||
| Retained Earnings | 407.35 M | ||||
| Working Capital | 939.25 M | ||||
| Current Asset | 103.25 M | ||||
| Current Liabilities | 18.78 M | ||||
About Repligen Performance
By examining Repligen's fundamental ratios, stakeholders can obtain critical insights into Repligen's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Repligen is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 130.53 | 133.81 | |
| Return On Tangible Assets | (0.02) | (0.02) | |
| Return On Capital Employed | (0.01) | (0.01) | |
| Return On Assets | (0.01) | (0.01) | |
| Return On Equity | (0.01) | (0.01) |
Things to note about Repligen performance evaluation
Checking the ongoing alerts about Repligen for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Repligen help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 634.44 M. Net Loss for the year was (25.51 M) with profit before overhead, payroll, taxes, and interest of 365.19 M. | |
| Repligen has a poor financial position based on the latest SEC disclosures | |
| Over 94.0% of the company shares are owned by institutional investors | |
| Latest headline from simplywall.st: Repligen Valuation Check As New Board Chair Signals Leadership Continuity |
- Analyzing Repligen's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Repligen's stock is overvalued or undervalued compared to its peers.
- Examining Repligen's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Repligen's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Repligen's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Repligen's stock. These opinions can provide insight into Repligen's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Repligen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. To learn how to invest in Repligen Stock, please use our How to Invest in Repligen guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Repligen. If investors know Repligen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Repligen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.6 | Earnings Share 0.02 | Revenue Per Share | Quarterly Revenue Growth 0.219 | Return On Assets |
The market value of Repligen is measured differently than its book value, which is the value of Repligen that is recorded on the company's balance sheet. Investors also form their own opinion of Repligen's value that differs from its market value or its book value, called intrinsic value, which is Repligen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Repligen's market value can be influenced by many factors that don't directly affect Repligen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Repligen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Repligen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Repligen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.